Safety population size and duration of exposure prior to approval of new medicines: A database analysis of medicines centralised approved in the European Union between 2011 and 2023
Fig 2
Boxplots with medians of the number of patients studied prior to approval according to the type of Marketing authorisation: standard (n = 392), conditional (n = 78) or approval under exceptional circumstances (n = 28). Boxplots present the 50th percentile, i.e., the median value is given, with the interquartile range (25th and 75th percentiles) indicated by the box, the 2nd and 98th percentiles indicated by the horizontal bars of the whiskers, and outliers indicated by individual circles. The total number of patients studied (y-axis) is plotted on a logarithmic scale.